Bosutinib and exemestane (EXE) versus EXE alone in postmenopausal (postm) women with hormone receptor-positive (HR+) HER2-negative (HER2-) advanced breast cancer (ABC).

被引：1
|
作者：
Moy, B.
Lebrun, F.
Bellet, M.
Chow, L.
Lang, I.
Xu, B.
Badwe, R. A.
Hershman, D. L.
Leip, E.
Bardy-Bouxin, N.
Duvillie, L.
Neven, P.
机构：
[1] Massachusetts Gen Hosp, Boston, MA 02114 USA
[2] Inst Jules Bordet, B-1000 Brussels, Belgium
[3] Vall dHebron Univ Hosp, Barcelona, Spain
[4] Unimed Med Inst, Comprehens Ctr Breast Dis, Hong Kong, Hong Kong, Peoples R China
[5] Orszagos Onkol Intezet, Budapest, Hungary
[6] Chinese Acad Med Sci, Canc Hosp, Beijing 100730, Peoples R China
[7] Tata Mem Hosp, Bombay 400012, Maharashtra, India
[8] Columbia Univ, Med Ctr, New York, NY USA
[9] Pfizer Inc, Cambridge, MA USA
[10] Pfizer Global Res & Dev, Paris, France
[11] UZ Leuven, Louvain, Belgium
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2011年 / 29卷 / 15期
关键词：
D O I：
10.1200/jco.2011.29.15_suppl.631
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
631
引用
收藏
页数：1
相关论文
共 50 条
  • [31] Everolimus in Combination with Exemestane: A Review of its Use in the Treatment of Patients with Postmenopausal Hormone Receptor-Positive, HER2-Negative Advanced Breast Cancer
    Sohita Dhillon
    Drugs, 2013, 73 : 475 - 485
  • [32] Everolimus in Combination with Exemestane: A Review of its Use in the Treatment of Patients with Postmenopausal Hormone Receptor-Positive, HER2-Negative Advanced Breast Cancer
    Dhillon, Sohita
    DRUGS, 2013, 73 (05) : 475 - 485
  • [33] Stomatitis following everolimus (EVE) plus exemestane (EXE) in patients with hormone receptor-positive (HR+), HER2-advanced breast cancer (ABC) in the BALLET trial (CRAD001Y1C04)
    Ciruelos, E. M.
    Jerusalem, G.
    Generali, D.
    Lang, I.
    Gavila, J. G.
    Michelotti, A.
    Tjan-Heijnn, V. C. G.
    Mariani, G.
    Conte, P.
    Beliera, A.
    Camozzi, M.
    Lorizzo, K.
    Martin, M.
    CANCER RESEARCH, 2016, 76
  • [34] FDA Approval: Ribociclib for the Treatment of Postmenopausal Women with Hormone Receptor-Positive, HER2-Negative Advanced or Metastatic Breast Cancer
    Shah, Anand
    Bloomquist, Erik
    Tang, Shenghui
    Fu, Wentao
    Bi, Youwei
    Liu, Qi
    Yu, Jingyu
    Zhao, Ping
    Palmby, Todd R.
    Goldberg, Kirsten B.
    Chang, C. J. George
    Patel, Paresma
    Alebachew, Elleni
    Tilley, Amy
    Pierce, William F.
    Ibrahim, Amna
    Blumenthal, Gideon M.
    Sridhara, Rajeshwari
    Beaver, Julia A.
    Pazdur, Richard
    CLINICAL CANCER RESEARCH, 2018, 24 (13) : 2999 - 3004
  • [35] PATTERNS OF CLINICAL MANAGEMENT AND RESOURCE UTILIZATION FOR POSTMENOPAUSAL HORMONE-RECEPTOR-POSITIVE HER2-NEGATIVE (HR+HER2-) ADVANCED BREAST CANCER (ABC) IN EUROPE
    Jerusalem, G.
    Marinsek, N.
    Ricci, J.
    Etchberger, J.
    Degun, R.
    Benelli, G.
    Saletan, S.
    Andre, F.
    ANNALS OF ONCOLOGY, 2012, 23 : 122 - 122
  • [36] Clinicopathologic features, genomic profiles and outcomes of younger vs. older Chinese hormone receptor-positive (HR+)/HER2-negative (HER2-) metastatic breast cancer patients
    Wang, Jinhao
    Liu, Yaxin
    Liang, Yuehua
    Zhang, Yue
    Dong, Hang
    Zheng, Tiantian
    Yu, Jianjun
    Du, Pan
    Jia, Shidong
    King, Bonnie L. L.
    Wang, Jing
    Liu, Xiaoran
    Li, Huiping
    FRONTIERS IN ONCOLOGY, 2023, 13
  • [37] Characterization of response to everolimus (EVE) in BOLERO-2: A phase 3 trial of EVE plus exemestane (EXE) in postmenopausal women with HR+, HER2-advanced breast cancer
    Burris, H.
    Gnant, M.
    Hortobagyi, G.
    Hart, L.
    Yardley, D. A.
    Eakle, J.
    Provencher, L.
    Brechenmacher, T.
    Saletan, S.
    Taran, T.
    Rugo, H.
    CANCER RESEARCH, 2013, 73
  • [38] Neoadjuvant therapy in hormone Receptor-Positive/HER2-Negative breast cancer
    Cantini, Luca
    Trapani, Dario
    Guidi, Lorenzo
    Bielo, Luca Boscolo
    Scafetta, Roberta
    Koziej, Marcin
    Vidal, Laura
    Saini, Kamal S.
    Curigliano, Giuseppe
    CANCER TREATMENT REVIEWS, 2024, 123
  • [39] EndoPredict® in early hormone receptor-positive, HER2-negative breast cancer
    K. Almstedt
    S. Mendoza
    M. Otto
    M. J. Battista
    J. Steetskamp
    A. S. Heimes
    S. Krajnak
    A. Poplawski
    A. Gerhold-Ay
    A. Hasenburg
    C. Denkert
    M. Schmidt
    Breast Cancer Research and Treatment, 2020, 182 : 137 - 146
  • [40] Molecular classification of hormone receptor-positive HER2-negative breast cancer
    Jin, Xi
    Zhou, Yi-Fan
    Ma, Ding
    Zhao, Shen
    Lin, Cai-Jin
    Xiao, Yi
    Fu, Tong
    Liu, Cheng-Lin
    Chen, Yi-Yu
    Xiao, Wen-Xuan
    Liu, Ya-Qing
    Chen, Qing-Wang
    Yu, Ying
    Shi, Le-Ming
    Shi, Jin-Xiu
    Huang, Wei
    Robertson, John F. R.
    Jiang, Yi-Zhou
    Shao, Zhi-Ming
    NATURE GENETICS, 2023, 55 (10) : 1696 - +
12345